ArticleChild and adolescent psychiatry and mental health2026
Efficacy of XRET in reducing anxiety symptoms and secondary effects on depression in adolescents with depressive disorder: a prospective non-randomized study.
Article in Child and adolescent psychiatry and mental health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundTo explore the therapeutic effects of different doses of Extended Reality Exposure Therapy (XRET) combined with pharmacotherapy on anxiety and depressive symptoms in adolescents with depressive disorders, and to verify the dose-response relationship and advantages of this combined treatment.
methodsA total of 142 patients were divided into the high-dose group (n = 32), medium-dose group (n = 45), low-dose group (n = 32), and monotherapy group (n = 33). Repeated measures analysis of variance (ANOVA) was used to compare intra-group differences in symptom change scores (anxiety, depression) before and after the intervention. One-way ANOVA and LSD post-hoc correction were applied for inter-group comparisons.
resultsAll four groups showed statistically significant improvements in anxiety and depressive symptoms after monotherapy or XRET-combined intervention (p < 0.001). The XRET dose groups demonstrated superior improvements in depression and anxiety symptoms compared to the monotherapy group (all p < 0.05). The medium-dose group exhibited the optimal improvement in depressive symptoms (ΔM = 16.16), which was significantly greater than that of the low-dose group (ΔM = 9.94; p < 0.001). There was also a statistically significant difference in depressive symptom improvement between the low-dose group and the high-dose group (ΔM = 13.97; p = 0.046), while no significant difference was observed between the medium-dose group and the high-dose group (p = 0.239). Regarding anxiety improvement, the difference between the low-dose group (ΔM = 9.75) and the medium-dose group (ΔM = 14.38) was statistically significant (p = 0.006).
conclusionsExtended Reality Exposure Therapy (XRET) combined with pharmacotherapy is effective in improving anxiety and depressive symptoms in adolescents with depressive disorders to a certain extent, with the medium-dose regimen yielding the optimal therapeutic benefit. Trial registration This study has been registered on the Chinese Clinical Trial Registry (Registration No.: ChiCTR2500099584)
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.